Related coverage linked through entity extraction aliases.
Jul 01, 2026
A study published in Menopause found that initiating hormone therapy after age 65 is associated with increased risks for any cancer and cerebrovascular accidents. The analysis of 83,147 women also showed elevated hazards for cancer and vascular events among those who initiated HT at ages 50 to 65.
Mar 19, 2026
A study of over 83,000 women found that initiating hormone therapy after age 65 significantly increases risks for cancer and cerebrovascular events, reinforcing current guidelines that discourage starting systemic hormone therapy after age 60.
Feb 13, 2026
The FDA removed black box warnings related to breast cancer, cardiovascular disease and dementia from six hormone replacement therapies for menopausal women, following a comprehensive review of scientific literature.
Feb 13, 2026
The FDA has approved labeling changes to six menopausal hormone therapy products, removing boxed warnings related to cardiovascular disease, breast cancer, and probable dementia that had been in place since 2003.
